Compare BridgeBio Pharma Inc (BBIO) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VF Corp — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while VF Corp trades at $16.55 (market cap $6.54B). The key difference: BridgeBio Pharma Inc is far larger — about 2.5× VF Corp's market cap, and VF Corp pays a 2.16% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | VFC | |
|---|---|---|
Market Cap | $16.46B | $6.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $21.55 |
52-Week Low | $44.81 | $11.66 |
Enterprise Value | $18.02B | $10.69B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VFC trades at $16.88, up 0.66% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Recent earnings show volatility with Q1 2026 missing estimates after previous beats. Revenue declined to $9.50B in 2025 with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a solid gross margin of 54.78% and reduced debt-to-asset ratio to 42.42% in 2025.
Outlook hinges on execution of turnaround efforts, particularly brand performance at Vans. Analyst consensus is mixed with a $19.33 price target suggesting 14.5% upside, but weak consumer spending and competitive pressures pose near-term risks. Cash flow improvement in 2026 projections and continued deleveraging provide potential catalysts if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
